sanuwave

Q3 2026
Business Update

Quarterly results, live presentation Wednesday, November 11, 2026.

Join us Wednesday, November 11, 2026 at 8:30 AM (ET)

01

PARTICIPANT DIAL-IN

Toll free

1-800-420-1459

Toll / international

1-203-518-9861

Conference ID

SANUWAVE

02

INSTANT TELEPHONE ACCESS

Click the link for instant telephone access to the event:

https://viavid.webcasts.com/starthere.jsp?ei=1777177&tp_key=6fc0abed5c

03

REPLAY DIAL-IN

Toll free

1-844-512-2921

Toll / international

1-412-317-6671

Replay PIN

11162619

Replay expiry

November 25, 2026

Forward-Looking Statements & Non-GAAP Financial Measures

FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, market acceptance of and demand for Ultramist, the estimated size of the wound care market, industry trends, regulatory actions that could adversely affect the price of or demand for the Company's approved products, the Company's ability to comply with the financial and other covenants under its credit agreement with JPMorgan Chase Bank, N.A., production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are: anticipated reimbursement levels for skin substitutes, allografts, or other advanced wound care products, and their effect on customer behavior and capital budgets; the financial distress, closure, or liquidation of wound care practices and the resulting impact on demand for the Company's systems; the emergence and growth of a secondary market for used Ultramist systems and the cannibalizing effect of such resales on sales of new systems; the Company's ability to qualify, train, and support new users acquiring systems through the secondary market, and the related regulatory, quality, and product-liability considerations; the Company's ability to sustain applicator and consumable volumes and convert system placements into recurring consumable revenue; risks associated with regulatory oversight; the Company's ability to regain and maintain compliance with Nasdaq listing requirements; the Company's ability to manage its capital resources; competition; and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

NON-GAAP FINANCIAL MEASURES


This presentation includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, or a replacement for, financial measures presented in accordance with U.S. GAAP.

The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges. EBITDA and Adjusted EBITDA should not be considered as alternatives to net (loss) income as a measure of financial performance or any other performance measure derived in accordance with U.S. GAAP, and they should not be construed as an inference that the Company's future results will be unaffected by unusual or infrequent items. These non-GAAP financial measures are presented in a consistent manner for each period, unless otherwise disclosed. The Company uses these measures for the purpose of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to U.S. GAAP measures, allows them to see the Company's results through the eyes of management, and to better understand its historical and future financial performance. These non-GAAP financial measures are also frequently used by analysts, investors, and other interested parties to evaluate companies in our industry, when considered alongside other U.S. GAAP measures.

Selected Financials — Q3 2026

(IN MILLIONS)

	Q3 2026	Q3 2025	YOY
Revenue	**$8.6**	$11.3	-24%
Gross profit	**$6.6**	$8.7	-24%
Gross margin %	**77.3%**	77.6%	-32 bp
Operating expense	**$7.7**	$7.8	-2%
Operating (loss) income	**($1.1)**	$0.9	-219%



EBITDA/Adjusted EBITDA Reconciliations

(IN THOUSANDS)	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,	
	2026	2025	**2026**	2025
Net (loss) income	$ (1,416)	$ 9,688	$ (3,537)	$ 4,121
NON-GAAP ADJUSTMENTS				
Interest expense	276	1,795	1,340	5,643
Depreciation and amortization [1]	341	264	948	757
Income tax expense	63	-	69	-
EBITDA	**(736)**	**11,747**	**(1,180)**	**10,521**
ADJUSTMENTS FOR ADJUSTED EBITDA				
Change in fair value of derivative liabilities	-	(6,097)	-	(2,186)
Stock-based compensation	1,480	1,397	4,622	3,513
Loss on extinguishment of debt	-	477	-	477
State & local sales tax [2]	(64)	383	(258)	1,088
Loss on impairment of assets	-	196	12	196
Severance agreement and legal settlement	-	113	-	113
Gain on license and option agreement	-	(5,000)	-	(5,000)
Sale of excess inventory	18	-	(202)	-
Adjusted EBITDA	**$ 698**	**$ 3,216**	**$ 2,994**	**$ 8,722**


See non-GAAP financial measures disclosure included on slide 3.

1 Depreciation and amortization excludes amortization of right-of-use (ROU) leases. Prior period amounts have been retroactively revised to conform to this presentation; this change had no effect on previously reported GAAP results.

2 The charges represent a non-recurring state and local sales tax (benefit) expense related to the restatement of prior period financial statements.

Ultramist Systems & Applicators Sales

Ultramist applicators and systems revenue, trailing five quarters



Revenue in millions

40

systems sold in Q3 2026, vs 155 in Q3 2025 and 82 in Q2 2026

ultramist®

Technology for healing.

